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Abstract
Different cells can contribute to repair following vascular injury by differentiating into smooth muscle (SM) cells; however
the extracellular signals involved are presently poorly characterized. Mesoangioblasts are progenitor cells capable of
differentiating into various mesoderm cell types including SM cells. In this study the biological action exerted by the
pleiotropic sphingolipid sphingosine 1-phosphate (S1P) in human mesoangioblasts has been initially investigated by cDNA
microarray analysis. Obtained data confirmed the anti-apoptotic action of this sphingolipid and identified for the first time a
strong differentiating action toward SM cells. Quantitative mRNA and protein analysis corroborated the microarray results
demonstrating enhanced expression of myogenic marker proteins and regulation of the expression of transcription factor
GATA6 and its co-regulator, LMCD1. Importantly, GATA6 up-regulation induced by S1P was responsible for the enhanced
expression of SM-specific contractile proteins. Moreover, by specific gene silencing experiments GATA6 was critical in the
pro-differentiating activity of the cytokine TGFb. Finally, the pharmacological inhibition of endogenous S1P formation in
response to TGFb abrogated GATA6 up-regulation, supporting the view that the S1P pathway plays a physiological role in
mediating the pro-myogenic effect of TGFb. This study individuates GATA6 as novel player in the complex transcriptional
regulation of mesoangioblast differentiation into SM cells and highlights a role for S1P to favour vascular regeneration.
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Introduction
Smooth muscle (SM) cells control many fundamental functions
such as arterial tone and airway resistance; alterations in vascular
SM cells contribute to a number of diseases in humans including
atherosclerosis and hypertension [1]. SM cells are not terminally
differentiated and are able to switch between a contractile and
synthetic phenotype in response to changing local environmental
cues [2]. A large number of factors including mechanical forces,
extracellular matrix components, endothelium-SM interactions
and transforming growth factor-b (TGFb) have been shown to
promote SM marker gene expression in cultured cell systems [1].
However, in contrast to skeletal muscle development, no master
genes have been found to regulate smooth muscle development,
although several genes such as myocardin, MRTFA, MRTFB,
Necdin and Msx2 have been found to be involved in the process
[3,4]. Several recent studies demonstrated that circulating, SM
progenitor cells can contribute to neointima formation and repair
following vascular injury [5].
Mesoangioblasts are a new type of progenitor cells, isolated
from explants of dorsal aorta, capable of differentiating into
various mesoderm cell types, such as smooth and striated muscle,
bone and endothelium [6]. When delivered in the left ventricle,
mesoangioblasts cause significant functional recovery despite
modest anatomical repair of infarcted cardiac muscle [7].
The sphingolipid metabolite sphingosine 1-phosphate (S1P) is a
lipid mediator that regulates fundamental biological processes
mainly through binding to its specific receptors S1P1–5 in many
cell systems [8]. S1P has recently been shown to have interesting
effects on vascular development and SM cells growth and
migration. S1P stimulates angiogenesis and induces vascular
maturation in many experimental models [9]. Recent literature
highlights the role of S1P in the regulation of proliferation,
survival, differentiation and migration of a range of adult and
embryonic stem cells [10]. We previously demonstrated that S1P
acts as potent mitogen and anti-apoptotic agent in murine and
human mesoangioblasts [11]. The important role of S1P in these
cells, is further supported by our finding that the anti-apoptotic
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action of transforming growth factor b (TGFb) involves the
regulation of sphingosine kinase (SphK)1, critically implicated in
S1P formation [12].
In order to completely utilize the therapeutic potential of these
cells, it is important to understand their intrinsic properties and the
role of the microenvironment in modulating their behaviour and
function. To this end, to fully individuate the potential biological
action of the pleiotropic cue S1P, we established transcriptional
profiles of human mesoangioblasts treated with the bioactive
sphingolipid. Presented results demonstrate that S1P promotes
differentiation of human mesoangioblasts towards SM cells by
transcriptional up-regulation of GATA6 and LMCD1.Moreover, we
present evidence that TGFb-induced differentiation of mesoangio-
blasts into SM relies on GATA6 and LMCD1 and that the induction
of these two transcription factors depends on SphK/S1P axis.
Methods
Materials
Biochemicals, cell culture reagents, Dulbecco’s modified Eagle’s
medium (DMEM), fetal calf serum (FCS), protease inhibitor
cocktail, bovine serum albumin (BSA), Tetramethylrhodamine B
isothiocyanate (TRITC)-phalloidin conjugate were purchased
from Sigma (St. Louis, MO, USA). RNeasy Micro Kit was from
Qiagen, (Valencia, CA, USA). TGFb1 and basic fibroblast growth
factor were purchased from PeproTech (London, UK). SKI-2 [2-
(p-hydroxyanilino)-4-(p11chlorophenyl)thiazole] and D-erythro-S1P
were from Calbiochem (San Diego, CA, USA). Enhanced
chemiluminescence (ECL) reagents were obtained from GE
Healthcare Europe GmbH (Milan, Italy). Coomassie Blue reagent
was from Bio-Rad (Hercules, CA, USA). Secondary antibodies
conjugated to horseradish peroxidase, anti-laminin, anti-calponin
1 (CNN1), anti-GATA6, anti-tropomyosin 1 (TPM1) antibodies,
and non fat dry milk were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Goat anti-transgelin
(TAGLN) antibodies was from Everest Biotech (Oxfordshire, OX,
UK). Fluorescein-conjugated horse anti-mouse and anti-rabbit
secondary antibodies were obtained from Vector (Burlingame,
CA, USA). High Capacity cDNA Reverse Transcription Kit and all
reagents and probes required to perform Real-Time PCR were
from Applied Biosystems Inc. (Foster City, CA, USA). Two short
interfering RNA (siRNA) duplexes corresponding to two DNA
target sequences of human GATA6 (59- GACAGAACGUGAUU-
CUCGUdTdT-39 and 59- GCUCAAGUAUUCGGGUCAA-
dTdT-39), human LMCD1 (59-GCCAUUACUGCGAGAGU-
CUdTdT-39 and 59-GGUCUACUCGGACAGGGCAdTdT-39),
one siRNA duplex corresponding to scrambled siRNA (59-
UUCUCCGAACGUGUCACGUdTdT-39), Mission siRNA du-
plex corresponding to DNA target sequences of human SphK1
(SASI Hs01_00169403) and Mission siRNA duplex corresponding
to DNA target sequences of human SphK2 (SASI Hs01_00158544)
were purchased from Sigma-Proligo (The Woodlands, TX, USA).
Lipofectamine RNAiMAXTM were purchased from Life Technol-
ogies (Carlsbad, CA, USA). MatrigelTM basement membrane
matrix was purchased from BD Biosciences (Bedford, MA, USA).
The specific S1P1/3 antagonist, VPC23019 [13] and the S1P2
antagonist JTE23019 [14] were obtained from Tocris Cookson
Ltd. (Bristol, UK). The ABCC1 inhibitor MK571 [15] was from
Enzo Lifesciences, (Farmingdale, NY, USA).
Cell culture
Human mesoangioblasts were routinely grown as previously
described [16].
For SM differentiation experiments, routine culture medium on
90% confluent cells was changed to DMEM and incubated with
0.11 mmol/L TGFb or 1 mmol/L S1P. In some experiments cells
were treated with 10 mmol/L SKI-2, 1 mmol/L VPC23019 and
1 mmol/L JTE013 45 min before agonist challenge.
Short interfering RNA administration
To silence SphK1, SphK2, GATA6 or LMCD1, mesoangio-
blasts were transfected with siRNA using a non specific siRNA as
control. Cells grown into 6-well dishes (80,000 cells/well) in Mega
Cell Medium supplemented with 5% heat inactivated FCS, were
transfected with the 21-nucleotide duplexes using RNAiMAXTM
Reagent according to manufacturer’s instructions as previously
demonstrated [17]. Briefly, RNAiMAXTM Reagent was incubated
with siRNA (200 nM) at room temperature for 20 min and
successively the lipid/RNA complexes were added with gentle
agitation to the cells. After 48 h from the beginning of transfection
cells were used for the experiments. To evaluate the specific knock-
down of target genes, quantitative Real-Time PCR was per-
formed.
cDNA microarray
Agilent whole human genome oligonucleotide microarrays
(44 K) were used to examine alterations in gene expression of
cells after S1P treatment (Agilent Technologies, Santa Clara, CA).
For the hybridization, 2 mg of total RNA were used. Labeling
reaction, hybridization and washing of the array were performed
following the protocols provided by Agilent according to the Two
color microarray-based gene expression analysis. Arrays were
scanned by using a 4000B Scanner (Axon Instruments, Union
City, CA, USA). Each hybridization produced a 16-bit image,
which was processed using the Agilent Feature Extraction software
(v8.1). In order to identify differentially expressed genes, the data
obtained from Feature Extraction were analyzed by ‘‘Significance
Analysis of Microarray’’ (SAM) algorithm [18] using the R
package siggenes.
All the statistical analyses were performed by using the statistical
language R [19].
Immunostaining and fluorescence microscopy
Cells were seeded on Lab-Tek II Chamber slides (Nalge Nunc
International, Naperville, IL, USA), challenged with 1 mmol/L
S1P or 0.11 mmol/L TGFb for 48 h and processed as previously
described [20]. Images were obtained using a Leica SP5 laser
scanning confocal microscope with 406 and 636 objectives.
Western blot analysis
Total cell lysates were prepared and subjected to SDS-PAGE
electrophoresis and Western analysis as previously described [21].
Quantitative Real-Time RT-PCR
Total RNA (2 mg), extracted with RNeasy Micro Kit from
human mesoangioblasts, was reverse-transcribed using High
Capacity cDNA Reverse Transcription Kit following the manu-
facturer’s protocols. The quantification of target gene mRNAs was
performed by Real-Time PCR employing TaqMan Gene
Expression Assays. Simultaneous amplification of the target
sequences (TPM1, Hs01576435_m1, CNN1, Hs00154543_m1,
GATA6, Hs00232018_m1, TRPS1, Hs00232645_m1, LMCD1,
Hs00205871_m1, Gene Expression assays, Applied Biosystems,
Foster City, CA) together with the housekeeping gene, 18S rRNA,
was carried out essentially as previously described [11]. The
22DDCT method was applied as a comparative method of
S1P Differentiates Mesoangioblasts
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20389
quantification [22] and data were normalized to ribosomal 18S
RNA expression.
In vitro morphogenesis assay
Matrigel (50 ml/well, 8–12 mg/ml) was pipetted into 13 mm
tissue culture wells and polymerized for 30 min to 1 h at 37uC, as
described [23]. Human mesoangioblasts were plated (206103/
well) in Mega Cell Medium, supplemented with 2% FCS in the
presence or absence of 1 mmol/L S1P or 10 mmol/L SKI-2. The
effects on the morphological changes of mesoangioblats were
recorded after 24 h with an inverted microscope (Leitz DM_IRB)
equipped with CCD optics and a digital analysis system.
Statistical analysis
Densitometric analysis of the Western Blot bands was
performed using ImageJ and reported as percentage relative to
the intensity of the band corresponding to control set as 100. Data
are expressed as means 6 S.E.M. of at least three experiments.
Statistical analysis was performed using Student’s t-test. Asterisks
indicate statistical significance: *P,0.05.
Results
A cDNA microarray study was performed to establish
transcriptional profiles of human mesoangioblasts treated with
the sphingolipid. For this purpose, when human mesoangioblasts
were 90% confluent, the medium was changed to DMEM
containing 0.1% BSA and further incubated in the presence of
1 mmol/L S1P for 6 h or 24 h.
In our set of four arrays 369 up-regulated and 166 down-
regulated genes were found to be significant (Supplemental table
S1,S2). As shown in Fig. 1, after analysis of the top 25 up-regulated
and top 25 down-regulated genes by S1P we found that genes
involved in apoptosis induction such as PMAIP1 and BBC3 were
significantly down-regulated. PMAIP1 and BBC3 encode for Noxa
and Puma respectively that belong to the BH3-only Bcl2 pro-
apoptotic family of proteins [24]. On the contrary, but consistently
with these results, the anti-apoptotic gene PPP1R13L, which
encodes for a protein that blocks apoptosis by presumably binding
and blocking p53, was found to be up-regulated following S1P
challenge [25]. The S1P-dependent regulation of genes involved in
apoptosis confirmed the anti-apoptotic role of this sphingolipid
previously demonstrated in these progenitor cells [11].
Moreover, as shown in Fig. 1, S1P regulated the expression of
genes involved in SM differentiation such as the transcription
factors GATA6 and TRPS1 and those encoding for SM contractile
proteins CNN1 and TPM1.
GATA6 is the only member of the GATA family transcription
factors that is expressed in VSMC [26] and is rapidly down-
regulated upon mitogen stimulation [27]. Although the down-
stream SM-specific genes targeted by GATA6 has yet to be
completely identified, it plays a crucial role in the maintenance of
the differentiated phenotype in VSMC [28]. Interestingly, in
concert with S1P-induced up-regulation of GATA6 expression,
TRPS1 which encodes for a nuclear protein that binds GATA
consensus motif and potently represses transcriptional activation
mediated by other GATA factors [29], was among the genes
maximally down-regulated following S1P treatment.
From the complete analysis of the microarray data (Supple-
mental tables S1,S2) emerged that the gene encoding for the LIM
domain protein, LMCD1, was significantly up-regulated after S1P
treatment. Expression of LMCD1 is remarkably similar to that of
GATA6, with high level of expression observed in vascular SM
cells and myocardium [30].
Notably, mRNA encoding for SM contractile apparatus
proteins such as CNN1, that binds very strongly to actin in a
Ca2+-independent manner, and the thin filament component
TPM1 were among the most significantly up-regulated by S1P
(Fig. 1). Furthermore, the expression of genes encoding for the
SM-specific actin-binding protein caldesmon (CALD1) and
TAGLN was also found to be significantly augmented (Supple-
mental table S1) supporting the view that not only S1P controls the
transcriptional machinery which gives rise to the SM phenotype
but S1P itself is also responsible for the onset of the differentiated
phenotype. From the analysis of the transcriptional profile, Necdin
and Msx2, previously identified as transcription factors required
for SM differentiation of mesoangioblasts [3,4], were not found to
be modified by S1P treatment.
Subsequently, in order to confirm the cDNA microarray
findings, we performed a Real Time RT-PCR analysis of specific
genes involved in SM differentiation that were differentially
expressed following S1P challenge. Mesoangioblast treatment with
1 mmol/L S1P for 6 h and 24 h significantly increased mRNA
levels of TPM1, GATA6, CNN1 and LMCD1, while it
significantly decreased that of TRPS1. These results are consistent
with that of the microarray data (Fig. 2A). The fold increase of
TPM1 and GATA6 mRNA expression levels were higher at 6 h,
while those of CNN1 and LMCD1 were higher at 24 h treatment
with the sphingolipid, indicating a different time-course of
expression for these genes. In agreement, GATA6 expression
was also found more potently increased by S1P at 6 h than at 24 h
in the cDNA microarray (Fig. 1).
Total lysates of serum-starved mesoangioblasts challenged with
1 mmol/L S1P for 24 h and 48 h were then analyzed by Western
blot analysis for SM contractile apparatus proteins CNN1 and
TPM1, and the transcription factor GATA6. S1P increased
protein levels of all investigated markers after 24 h of incubation
and its effect was still significant at 48 h (Fig. 2B). The
morphological change provoked by this bioactive sphingolipid
was clearly appreciable by confocal immunofluorescent micro-
scopic analysis of mesoangioblasts performed to reveal the state of
assembly of the cytoskeleton. Indeed, cell incubation with 1 mmol/
L S1P for 48 h, profoundly altered the organization of actin
cytoskeleton, giving rise to the formation of numerous F-actin
filaments organized as stress fibers anchored to the plasma
membrane, which were immunorevealed by TRITC-phalloidin
(Fig. 2C). Notably, the same figure shows that a certain number of
mesoangioblasts (approximately 30–40%) was strongly positive to
the antibodies against CNN1 and TPM1 after S1P treatment.
Thus, data presented in Figs. 2B and 2C demonstrate that the
effect elicited by S1P on mesoangioblast protein levels was
consistent with changes of the transcriptional profile induced by
this sphingolipid.
The involvement of S1PR in the differentiating action of S1P
was next examined. Interestingly, as shown in Fig. 2D, pre-
incubation of human mesoangioblasts with the specific antagonist
of S1P1/3 VPC23019 (1 mmol/L) or the specific antagonist of S1P2
JTE013 (1 mmol/L) completely abolished the increase of the SM
marker CNN1 induced by 1 mmol/L S1P, suggesting that S1P2
and S1P1/3 receptors mediate distinct molecular events necessary
for the differentiation to occur.
Given that GATA6 is recognized as a transcription factor
critical for SM differentiation [31], to better characterize the
increase of this transcription factor induced by S1P, we next
determined if the sphingolipid augmented GATA6 mRNA
expression levels in a dose-dependent manner. As shown in
Fig. 3A, the sphingolipid was efficacious in upregulating GATA6
mRNA at a concentration of 100 nmol/L up to 1 mmol/L, while
S1P Differentiates Mesoangioblasts
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was ineffective at a higher concentration, in keeping with the
affinity towards S1P exhibited by its receptors.
Moreover, we next investigated by Real Time PCR whether the
up-regulation of the transcription factor GATA6 and LMCD1
mRNA content elicited by S1P was involved in the induction of
the myogenic marker CNN1. As illustrated in Fig. 3B, GATA6
knock-down by specific RNA silencing almost abolished the S1P-
dependent enhancement of CNN1 mRNA. The positive effect of
S1P on the myogenic marker mRNA levels was also abolished by
LMCD1 silencing. In perfect agreement, the down-regulation of
GATA6 or LMCD1 mRNA abolished the S1P-induced increase
of mRNA encoding for another key myogenic marker such as
TPM1 (Fig. 3C).
To gain insight into themechanismbywhichGATA6andLMCD1
are necessary for the induction of expression of proteins characteristic
of SM phenotype such as CNN1 and TPM1, their mRNA content in
response to S1P administration was evaluated when one of the two
transcriptional regulators was specifically silenced. Data reported in
Fig. 3D show that GATA6mRNA up-regulation induced by S1P was
strongly reduced by LMCD1 silencing; likewise, knock-down of
GATA6 was responsible for a markedly diminished effect of S1P on
LMCD1 mRNA content (Fig. 3E). Thus, reciprocal regulation of
GATA6 and LMCD1 mRNA levels accounts for the observed dual
control of SMmarker proteins by S1P.
The role of GATA6 and LMCD1 in the transcriptional
regulation triggered by S1P in mesoangioblasts was further
investigated by examining their involvement in the down-
regulation of the GATA repressor TRPS1. Specific siRNA
targeted to GATA6 did not influence the potent inhibitory effect
of S1P on TRPS1 mRNA expression, whereas the efficacy of S1P
was strongly attenuated when LMCD1 was silenced, clearly
demonstrating that LMCD1 acted also independently from
GATA6 regulation (Fig. 3F).
The current view indicates that a functional cross-talk between
TGFb and S1P signaling occurs in some cell types [32–35]. In this
regard, we previously showed that TGFb-dependent SphK/S1P
axis is critical for the anti-apoptotic effect of the cytokine in
mesoangioblasts [12]. Therefore, since TGFb is a strong inducer
of mesoangioblast differentiation towards SM [36], we examined
whether SphK might be involved also in this TGFb-induced effect.
Indeed, incubation of cells with the specific SphK inhibitor SKI-2
(10 mmol/L) 45 min before TGFb challenge, significantly reduced
the increase of TPM1 and completely inhibited that of CNN1 at
mRNA level (Fig. 4A). Consistently, at protein level, the blockade
of SphK activity markedly reduced the increase of CNN1 and
TPM1 (Fig. 4B). Analogously, in these experimental conditions,
the cytokine-increased expression of other SM markers, such as
TAGLN and laminin was strongly impaired and abolished,
respectively (Fig. 4B). In agreement, confocal immunofluorescence
analysis revealed that the significant increase of TPM1 and
TAGLN expression following treatment with 0.11 mmol/L TGFb
was completely inhibited by pre-incubation with 10 mmol/L
Figure 1. cDNA microarray analysis. The heat map shows the top 25 down-regulated (left, green) and top 25 up-regulated (right, red) genes. On
the left and right side d-values and gene names are reported respectively. Columns 1–2 represent S1P stimulation for 6 h and columns 3–4 represent
S1P stimulation for 24 h.
doi:10.1371/journal.pone.0020389.g001
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SKI-2 (Fig. 4C). In order to identify which of the two SphK
isoforms is required for the TGFb-induced effect, SphK1 and
SphK2 were specifically down-regulated by RNA interference in
human mesoangioblasts before being challenged for 48 h with
0.11 mmol/L TGFb. Down-regulation of SphK1 or SphK2
resulted in a significant reduction of the expression of the SM
marker CNN1 increased by the cytokine (Fig. 4D), suggesting the
involvement of both isoforms in the observed effect.
Finally, in order to clarify whether the activation of SphK/S1P
axis by TGFb results in the release of the sphingolipid into the
medium, we pre-treated mesoangioblasts with 15 mmol/L
MK517, an inhibitor of ABCC1 transporter [15], 45 min before
challenge with the cytokine. The blockade of ABCC1 transporter
completely inhibited the increase of the SM marker TPM1
induced by the cytokine, identifying the transporter as responsible
for this autocrine/paracrine pathway in these cells (Fig. 4E).
Overall, these latter results support the view that TGFb-induced
differentiation of mesoangioblasts towards SM depends on SphK/
S1P axis.
In view of the here reported involvement of GATA6 and
LMCD1 in the differentiating action of S1P, we next determined
whether they were also involved in the mechanism by which
TGFb drives differentiation towards SM. As illustrated in Fig. 5A,
GATA6 knock-down by specific RNA silencing strongly reduced
the TGFb-dependent enhancement of TPM1 mRNA and
completely blocked that of the other key myogenic marker
CNN1. Similarly, the down-regulation of LMCD1 mRNA
abolished the TGFb-induced increase of mRNA encoding for
both SM markers TPM1 and CNN1. Interestingly, data presented
in Fig. 5B show that TGFb, similarly to S1P, was responsible for
an increase of GATA6 mRNA content which was strongly
reduced when SphK was pharmacologically inhibited. Likewise,
SphK was involved in the increase of LMCD1 mRNA elicited by
TGFb (Fig. 5C). Thus, these results highlight a role for GATA6
and LMCD1 in the mechanism by which TGFb exerts its pro-
myogenic action.
Finally, we sought to evaluate the effect of S1P on morpholog-
ical differentiation of mesoangioblasts. To this end, to better
explore the phenotypic changes promoted by S1P in human
mesoangioblasts, cells seeded in Matrigel and treated with
1 mmol/L S1P were observed at 24 h (Fig. 6A). The addition of
the bioactive sphingolipid induced more profound morphological
changes compared to unchallenged cells, demonstrating that, in
addition to modulate the expression of SM markers, S1P acts as a
real differentiating cue in these cells. Since a certain level of
differentiation was also appreciable in unchallenged mesoangio-
blasts at 24 h, we sought to evaluate whether an endogenously
produced S1P by activated SphK might be responsible for the
Figure 2. Effect of S1P on mRNA (A) and protein (B,C) expression levels of SM markers in human mesoangioblasts. Role of S1PR (D).
Cells were incubated in DMEM with S1P and analyzed by A) Real-Time PCR; B) Western blot analysis; (lower panel represents densitometric
quantification) and C) Confocal microscopy analysis (406magnification) using TRITC-phalloidin and anti-fluorescein conjugated specific antibodies.
D) Cells were pre-incubated with VPC23017 and JTE071 in DMEM before being challenged with S1P and analyzed by Western blot analysis for CNN1
(lower panel represents densitometric quantification).
doi:10.1371/journal.pone.0020389.g002
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observed effect. Indeed, incubation of the 3D matrigel culture of
mesoangioblasts in the presence of 10 mmol/L SKI-2, significantly
impaired the appearance of the differentiated phenotype (Fig. 6B).
Although SphK plays a crucial role in the survival of mesoangio-
blasts [12], the presence of serum in the growing medium
prevented the onset of the apoptotic cell death (data not shown).
These findings confirm the crucial role of SphK/S1P axis in the
induction of differentiation towards SM of these mesenchymal
progenitors.
Discussion
The interplay between extracellular signals and transcriptional
regulation is a crucial nexus of control for cell lineage
determination. Thus, competence to respond to the milieu of
local growth factors is a fundamental determinant of the eventual
fate of multipotent cells. In this regard, S1P, that can be locally
produced in autocrine manner in response to the cytokine TGFb
and many diverse growth factors, deserves considerable attention
in view of its pleiotropic mode of action.
Remarkably, in this study the analysis of transcriptional profile
of human mesoangioblasts in response to S1P treatment not only
confirms that this sphingolipid is a powerful anti-apoptotic agent
but highlights for the first time its role as morphogenetic cue that,
up-regulating GATA6 and LMCD1 transcription factors as well as
SM contractile proteins including TPM1, CNN1, TAGLN and
CALD1, triggers differentiation of these progenitor cells towards
SM phenotype. In addition to the cDNA microarray study,
multiple experimental evidence for the pro-differentiating activity
of S1P in mesoangioblasts is here provided: the enhanced
expression of transcriptional regulators and structural SM-specific
proteins was validated by Real time PCR; moreover, Western
blotting and confocal microscopy analysis further confirmed the
S1P-mediated biological effect. Furthermore, morphological
analysis of cells grown on Matrigel revealed that S1P provoked
profound phenotypic modifications which were consistent with the
accomplishment of a functional SM phenotype.
Interestingly, here by siRNA-mediated gene silencing, GATA6
and LMCD1 have been identified as novel transcriptional
regulators of mesoangioblast differentiation towards SM. Notably,
experimental evidence is provided that this novel molecular
mechanism of transcriptional control of SM phenotype appear-
ance is integral to the biological action exerted by TGFb in these
cells.
Modulation of S1P metabolism as well as S1P availability at the
site of vascular lesion appears to be highly relevant for switching
between different SM phenotypes in physiological and patholog-
ical conditions. Indeed, previous studies by Lockman et al. [37]
have shown that treating SM cells with S1P increased their
proliferation and paradoxically increased the expression of
Figure 3. Dose-dependence of GATA6 expression level induced by S1P (A) and role of the transcription factors GATA6, LMCD1
(B,C) on the expression levels of SM markers induced by S1P in mesoangioblasts. Mutual regulation of the transcription factors GATA6,
LMCD1 and TRPS1 (D,E,F). Real time PCR analysis of GATA6 (A) was performed in cells challenged with the indicated concentrations of S1P for 6 h.
Real-Time PCR analysis of CNN1 (B), TPM1 (C), GATA6 (D), LMCD1 (E), TRPS1 (F) was performed in cells transfected with scrambled-, GATA6- or LMCD1-
siRNA and stimulated with S1P for 24 h.
doi:10.1371/journal.pone.0020389.g003
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SM-specific a-actin and myosin as well as TAGLN. Subsequently,
Wamhoff et al. demonstrated that S1P receptors are differentially
affected by vascular injury and that S1P1/3 negatively regulate the
phenotypical appearance of contractile protein and positively
regulate proliferation, while, S1P2 opposes these actions [38].
Here, on the contrary, by pharmacological inhibition, S1P2 and
S1P1/3 were found to be involved in the differentiating action of
S1P towards SM of these progenitor mesodermal cells, in
agreement with what previously reported in adipose tissue-derived
mesenchymal stem cells where S1P2 and, at a lesser extent S1P3,
turned out to be critical for the pro-differentiating effect of S1P
[20]. The role of S1P2 in SM differentiation was also recently
confirmed since its activation was required for the expression of
SM-specific a-actin after arterial injury [39] and LARG-mediated
RhoA activation leading to SM differentiation [40]. Additionally,
the expression of SM-specific a-actin induced by TGFb in C2C12
myoblasts was found to be downstream of S1P/S1P3 axis [41].
Moreover, S1P induces Ca2+-dependent contraction, prolifera-
tion and migration of SM cells [9]. Finally, genetically null mice
for S1P1 are embryonically lethal due to impaired homing of SM
cells to developing blood vessels, highlighting the importance of
the S1P signalling via S1P1 for vascular SM cell migration [42]. In
the last few years, studies examining the role of S1P on vascular
function support the notion that the multiple effects elicited by this
sphingolipid could represent potential therapeutic targets for
angiogenesis, atherosclerosis and vascular injury. This is not only
due to its multiple effects on cardio-vascular system but also
because S1P plays an important role in the regulation of
embryonic and adult stem cells [43]. In this regard S1P appears
to play a dual role, since it maintains human embryonic stem cells
in undifferentiated state [10] and acts as a differentiating cue in
toti- or multi-potent cells: it induces cardiac differentiation of
embryoid bodies derived from mouse embryonic stem cells [44]
and up-regulates the expression of SM marker proteins of adipose
tissue-derived mesenchymal stem cells [20], reinforcing the notion
of a pleiotropic action of this lipid. Despite this conspicuous
amount of information, little is known about the eventual
transcription regulators that orchestrate the expression of tissue-
specific proteins under the control of S1P, with the notable
exception of cofactors of the myocardin family found implicated in
differentiation of vascular rat SM cells [37]. The present finding
that knock-down of GATA6 abrogates the S1P-induced expression
Figure 4. Effect of SphK inhibition (A,B,C), dowregulation (D) and ABCC1 transporter inhibition (E) on the expression levels of SM
markers induced by TGFb treatment in human mesoangioblasts. Cells were pre-treated with SKI-2 45 min before being incubated with
DMEM for 48 h with TGFb and analyzed by A) Real-Time PCR analysis B) Western blot analysis and C) Confocal microscopy analysis (636
magnification) using anti fluorescein-conjugated specific antibodies. D) Cells were transfected with scrambled-, SphK1-, SphK2-siRNA, stimulated with
TGFb and analyzed by Western blot analysis for CNN1. Lower panel represents densitometric quantification. E) Cells were pre-treated with MK571
45 min in DMEM before being incubated with TGFb for 48 h and analyzed by Western blot analysis for TPM1. Lower panel represents densitometric
quantification.
doi:10.1371/journal.pone.0020389.g004
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of SM-specific proteins identifies this transcription factor as main
responsible for differentiation of mesoangioblasts towards SM
cells. Intriguingly, GATA6 was recently found involved in the
differentiation of mesoangioblasts isolated from ventricular vessel
towards cardiomyocytes [45]; interestingly, here, from cDNA
microarray study troponin C mRNA was not affected (Supple-
mental table S1,S2), nor its protein content examined by Western
blot analysis was changed (data not shown).
Additionally, in the present study in agreement with a key role
of GATA6, TRPS1 which is a potent repressor of GATA
transcriptional activity [29] was found dramatically down-
regulated by S1P treatment. Moreover, besides GATA6, S1P
significantly enhanced mRNA content of a co-regulator of GATA
family protein, LMCD1, in accordance with its tissue expression
pattern similar to that of GATA6 [30]. Interestingly, here GATA6
and LMCD1 were found both required for the expression of SM-
specific proteins and subjected to mutual regulation of their
mRNAs. Since LMCD1 has been reported to act also as a co-
repressor of GATA6 [30], the present data exclude that this
possibility holds true in the mechanism by which S1P promotes
SM differentiation of mesoangioblasts, rather supporting its
positive role on GATA6 expression.
Previously it has been shown that mesoangioblasts express many
members of the TGFb/BMP pathway and promptly differentiate
into SM cells in response to TGFb [36]. Although serum response
cofactor myocardin, MRTFA and Mrf2-a and -b are known to
play a fundamental role in SM differentiation [2], TGFb-mediated
differentiation of these cells into SM is myocardin-independent
[3]. Two transcription factors, Necdin and Msx2, are up-regulated
in response to TGFb and are sufficient to induce some SM
markers such as SM-specific myosin [3]. From the analysis of the
present transcriptional profile, Necdin and Msx2 appear to be not
influenced by S1P treatment, which instead was discovered to rely
on GATA6 up-regulation for transmitting its biological effect, thus
supporting the notion that the complex process of mesoangioblast
differentiation into SM is orchestrated by multiple transcription
factors.
In light of the functional cross-talk that occurs between TGFb
and S1P signaling pathways in various cell types [32–35],
mesoangioblasts included [12], here the mechanism by which
TGFb drives mesoangioblasts towards SM phenotype was further
explored. Similarly to what observed for S1P, TGFb was found
not only to enhance the expression of GATA6 and LMCD1, but
also to depend on these transcriptional regulators for the up-
regulation of the SM-specific proteins, TPM1 and CNN1.
Importantly, the effect of TGFb on GATA6 and LMCD1 was
severely impaired when the biosynthesis of S1P was pharmaco-
logically and genetically prevented. Hence, the here identified
S1P-dependent novel molecular mechanism for triggering differ-
entiation of mesoangioblasts towards SM cells has physiological
Figure 5. Role of GATA6 and LMCD1 transcription factors on the expression levels of SM markers induced by TGFb in human
mesoangioblasts (A) and their dependence on SphK activity (B,C). Cells transfected with scrambled-, GATA6-, LMCD1-siRNA A) and pre-
treated with SKI-2 for 45 min (B,C) were stimulated with TGFb and analyzed by Real-Time PCR.
doi:10.1371/journal.pone.0020389.g005
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relevance since it is exploited by TGFb for exerting its
morphogenetic action. Moreover, by specific silencing of SphK1
and SphK2, in human mesoangioblasts the pro-differentiating
action of the cytokine was found to depend on both isoforms of
SphKs, and the subsequent release of S1P into the media through
the ABCC1 transporter as here demonstrated by pre-treatment
with the inhibitor MK571 and as already reported in other cell
types [15]. However, attempts made to measure S1P into the
medium were unsuccessful possibly due to the partition of this
sphingolipid into plasma membrane microdomains rather than its
release in the extracellular environment (data not shown).
Intriguingly, CNN1, here identified downstream of GATA6, is
not a downstream target of Necdin or Msx2 in mesoangioblasts
challenged with TGFb 3, reinforcing the hypothesis that up-
regulation of GATA6 by TGFb is necessary to induce its full
biological effect in these cells. It will be interesting to examine in a
future study the eventual interplay among Necdin, Msx2 and
GATA6 in the regulation of SM phenotype by TGFb in these cells
and their hierarchical relationship, possibly extending the
investigation to Notch signaling, recently reported to be involved
in TGFb-dependent SM differentiation of mesenchymal stem cells
[46].
Overall this study increases our knowledge of the role of S1P in
these progenitors cells as differentiating cue. Intriguingly, S1P and
TGFb, here demonstrated to share molecular mechanisms
essential to drive mesoangioblast differentiation, were previously
identified as anti-apoptotic cues in these cells [11,12]; moreover,
SphK1 up-regulation by TGFb was found critical for the
protective role of the cytokine [12]. Whether the prevention of
apoptotic death is a determining factor for the successful
differentiation of these progenitors cells remains however to be
established.
As regards the possible intervention in regenerative medicine,
in the last few years studies examining the role of S1P on vascular
function support the notion that the multiple effects elicited by
this sphingolipid could represent potential therapeutic targets for
angiogenesis, atherosclerosis and vascular injury. Blood vessel
replacement is frequently necessary in the treatment of advanced
atherosclerosis and vascular trauma. The emerging field of tissue
engineering represents a mean to construct functional grafts when
autologous tissue is unavailable due to donor site morbidity.
Replacement vessels are engineered in vitro by seeding polymeric
tubular scaffolds with autologous endothelial and SM cells [47].
The results of the present study suggest that mesoangioblasts,
relatively easy to obtain with an extensive in vitro proliferation
capacity, could be potentially used as a source of SM cells for
cellular therapeutics and tissue engineering.
In conclusion, in this study we demonstrate that S1P induces
differentiation of mesoangioblasts mesenchymal stem cells
towards a SM phenotype. Importantly, GATA6 up-regulation,
together with that of LMCD1, was identified as a novel
mechanism of transcriptional regulation that drives SM differen-
tiation of mesoangioblasts. Moreover, we provide evidence that
GATA6 plays also a role in the mechanism by which TGFb
trigger SM differentiation of mesoangioblasts and that S1P
biosynthesis is required for the accomplishment of the biological
action of the cytokine. The present results represent an original
contribution to the knowledge of the molecular mechanisms that
regulate differentiation of these progenitors cells and disclose
SphK/S1P axis as an attractive novel target to stimulate
Figure 6. Role of SphK/S1P axis on morphogenesis of mesoangioblasts seeded on Matrigel. 206103 cells were plated in Matrigel in the
presence of S1P (A) with or without SKI-2 (B) and photographed (106magnification) at time 0 and after 24 h from plating.
doi:10.1371/journal.pone.0020389.g006
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differentiation of mesoangioblasts towards a SM contractile
phenotype.
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